A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
A new report from GlobalData UK indicates that the market for HER2-positive breast cancer treatments could grow from $6.4 billion in 2015 to $9.89 billion in 2025, a compound annual growth rate (CAGR) of 4.4%.
The report, which examines the HER2-positive treatment market in the United States, the United Kingdom, France, Germany, Italy, Spain, Japan, and China, indicates that the adjuvant and neoadjuvant settings of the market, which the report’s authors say will reach $4.96 billion by 2025, are likely to emerge as the main drivers of sales. The biggest sales driver is expected to be the monoclonal antibody pertuzumab (Roche’s Perjeta) used in first-line therapy for HER2-positive metastatic breast cancer in combination with trastuzumab (Herceptin) and docetaxel.
Because pertuzumab and the reference trastuzumab are believed to work in complementary ways to increase death of cancer cells, increased use of pertuzumab could help protect sales of Herceptin in a landscape with growing numbers of biosimilar options, the authors say. Perjeta will also extend the duration of treatment, contributing to higher sales numbers.
Max Bourgognon, healthcare analyst for GlobalData, explained the staying power of the monoclonal antibodies in the marketplace, saying, “The dynamism of the adjuvant and neoadjuvant markets has prompted many companies to position their products in these settings. However, many agents have failed to demonstrate clinical benefit over the currently cemented standard of care, meaning the adjuvant and neoadjuvant settings will remain an exclusive market for anti-HER2 monoclonal antibodies, hence constituting the most lucrative opportunity for biosimilar developments.”
The report also indicates that the anticipated launch of Puma Biotechnology's neratinib in late 2017 could create a new treatment setting for the treatment of HER2-positive breast cancer: the extended adjuvant setting, a currently underexplored area that could boom as additional drug manufacturers seek market share. Neratinib, a tyrosine kinase inhibitor (TKI), blocks signal transduction through the epidermal growth factor receptors HER1, HER2, an HER4. Puma Biotechnology says that it sees the potential for the oral treatment to be used in several additional indications, including gastric cancer. The drug was recommended for approval by the FDA's Oncologic Drugs Advisory Committee (ODAC) in May.
As promising as new TKIs may be, the report notes that there remains room for new products, and that patients who have TKI-resistant HER2-positive cancer remain an especially underserved segment of the patient population that will require innovative therapies to meet their needs.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
AAM Report: Despite Massive Savings, Patient OOP Costs on Biosimilars, Generics Remain High, Part 2
September 24th 2024Part 2 of our series diving into the Association for Accessible Medicines' (AAM) latest report discusses that while generics and biosimilars saved $445 billion in 2023, their potential is hindered by high patient costs, drug shortages, and ineffective policies, underscoring the need for reforms to fully realize their benefits.
Exploring the Biosimilar Horizon: Julie Reed's Predictions for 2024
February 18th 2024On this episode of Not So Different, Julie Reed, executive director of the Biosimilars Forum, returns to discuss her predictions for the biosimilar industry for 2024 and beyond as well as the impact that the Forum's 4 new members will have on the organization's mission.
AAM Report: Generics and Biosimilars Savings Reach $445 Billion in 2023, Part 1
September 18th 2024Savings from generic and biosimilar drugs totaled $445 billion in 2023, showing promise for the growth of both markets and highlighting the success of expansion policies for these products, according to a new report from the Association for Accessible Medicines (AAM).